BenevolentAl Therapeutics Pipeline and Triage
BenevolentAl pipeline assets target treatment of
prevalent diseases with high unmet need
BEN-2293 for the treatment of Atopic Dermatitis
BEN-2293 is a first-in-class, topical, steroid sparing PanTrk antagonist
to address itch and inflammation in mild-moderate atopic dermatitis
Illustrative target patient population in 2020
All atopic dermatitis patients¹
Patients with mild-moderate disease¹
Treatable population
BEN-8744 for the treatment of Ulcerative Colitis
BEN-8744 is an oral, peripherally restricted, potent and selective PDE10
inhibitor for the treatment of moderate-to-severe Ulcerative Colitis
Illustrative target patient population in 2020
All ulcerative colitis patients³
0.62M US | 0.86M EU5 | 0.15M JP
43.4M US | 33.9M EU5 | 5.1M JP
82.6% US | 45.2% EU5 | 55.5% JP
35.8M US | 15.3M EU5 | 2.8M JP
Patients with moderate-severe disease³
Treatable population
42.6% US | 39.9% EU5 | 32.0% JP
0.26M US | 0.34M EU5 | 0.05M JP
Illustrative approved therapies
Dupilumab (Dupixent, AD launch 2017)2
(Subcutaneous injection, mAb, anti IL4/IL13)
2020 Net Revenue
$3.2B WW (Atopic Derm Only)²
Illustrative pipeline / recently approved therapies
Illustrative approved therapies
Adalimumab (Humira, UC launch 2012)7
(Subcutaneous injection, mAb, anti TNF)
Vedolizumab (Entyvio, UC launch 2014)8
(Subcutaneous injection, mAb, anti a4ẞ7 integrin)
2020 Net Revenue
$2.6B WW (UC Only)
$2.0B WW (UC Only)
Illustrative pipeline / recently approved therapies
Ruxolitinib (Opzelura, AD launch 2021)9
(Topical cream, JAK inhibitor; expected cost ~$8,000
patient/year in US5)
Peak Sales Forecast
$1.1Bn WW (Atopic Derm Only)
Ozanimod (Zeposia, UC launch 2021)6
(oral, small molecule, SIP1/S1P5 modulator, $86,000
patient/year in US³)
Peak Sales Forecast
$3.0B WW (UC Only) 6
Sources: (1) Global Data Atopic Dermatitis: Epidemiology Forecast to 2027, 28 November 2018; (2) Evaluate Pharma Product Report - Dupixent [Accessed 29 Oct 2021]; (3) Global Data Ulcerative Colitis Drug Forecast and Market Analysis to 2029; (4) Endpoints/Andrew Berens at SVB
Leerink; (5) Incyte Opzelura approval investor call 22 September 2021; (6) FiercePharma/Salim Syed at Mizuho Securities; (7) Evaluate Pharma Product Report - Humira [Accessed 01 Nov 2021]; (8) Evaluate Pharma Product Report - Entyvio [Accessed 01 Nov 2021]; (9) Evaluate Pharma
Product Report - Opzelura [Accessed 29 Oct 2021]
Benevolent 71
AlView entire presentation